Raymond James Initiates Coverage On Taysha Gene Therapies with Strong Buy Rating, Announces Price Target of $13
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Raymond James analyst Christopher Raymond initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Strong Buy rating and announces Price Target of $13.
Raymond James analyst Christopher Raymond initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Strong Buy rating and announces Price Target of $13.